Reconsidering Prostate Cancer Mortality - The Future of PSA Screening

Affiliations

¹ From the Center for Surgery and Public Health, Brigham and Women's Hospital, Boston (H.G.W.); and the Division of Urology, Department of Surgery, University of Connecticut Health Center, Farmington (P.C.A.).

H Gilbert Welch et al. N Engl J Med. 2020.

. 2020 Apr 16;382(16):1557-1563.

doi: 10.1056/NEJMms1914228.

¹ From the Center for Surgery and Public Health, Brigham and Women's Hospital, Boston (H.G.W.); and the Division of Urology, Department of Surgery, University of Connecticut Health Center, Farmington (P.C.A.).

No abstract available

Comment in

Re: Reconsidering Prostate Cancer Mortality - The Future of PSA Screening: The future of PSA screening by reconsidering prostate cancer mortality.
Borghesi M, Suardi N, Terrone C. Borghesi M, et al. Eur Urol. 2020 Dec;78(6):929. doi: 10.1016/j.eururo.2020.06.028. Epub 2020 Jul 1. Eur Urol. 2020. PMID: 32622550 No abstract available.
Re: Reconsidering Prostate Cancer Mortality - The Future of PSA Screening: Against increasing PSA threshold to 10 ng/ml.
R Zlotta A, V Carlsson S, Finelli A, E Fleshner N. R Zlotta A, et al. Eur Urol. 2020 Dec;78(6):927-929. doi: 10.1016/j.eururo.2020.06.026. Epub 2020 Jul 2. Eur Urol. 2020. PMID: 32624274 No abstract available.